Editorial
Osimertinib in advanced EGFR T790M-positive non-small-cell lung cancer: the clinical impact of AURA3
Letter to the Editor
Disclosure:
This supplement was published without any sponsorship or funding.
Disclosure:
This supplement was published without any sponsorship or funding.